Page 53 - Demo

N-of-1 studies in rare genetic neurodevelopmental disorders512References1. European Parliament C of the EU. Regulation (EC) N°141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products 2000. Official Journal of the European Communities. Available at: https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/reg_2000_141_cons-2009-07/reg_2000_141_cons-2009-07_en.pdf. Accessed February 20, 2020. 2. European Organisation for Rare Diseases (EURORDIS): Rare diseases: understanding this public health priority 2005. https://www.eurordis.org/IMG/pdf/princeps_document-EN.pdf. Accessed February 20, 2020. 3. Morant AV, Jagalski V, Vestergaard HT. Labeling of Disease-Modifying Therapies for Neurodegenerative Disorders. Frontiers in medicine 2019;6:223. 4. Vernon HJ. Inborn errors of metabolism: Advances in diagnosis and therapy. JAMA Pediatrics 2015;169(8):778-782. 5. Guyatt G, Sackett D, Adachi J, et al. A clinician’s guide for conducting randomized trials in individual patients. Canadian Medical Association Journal 1988;139(6):497. 6. Shamseer L, Sampson M, Bukutu C, et al. CONSORT extension for reporting N-of-1 trials (CENT) 2015: Explanation and elaboration. BMJ 2015;350:1793.7. OCEBM Levels of Evidence Working Group. The Oxford levels of Evidence 2. Oxford Centre for Evidence-Based Medicine 2011. Available at: www.cebm.net/index.aspx?o=5653. Accessed February 20, 2020. 8. Porcino AJ, Shamseer L, Chan AW, et al. SPIRIT extension and elaboration for n-of-1 trials: SPENT 2019 checklist. BMJ. 2020;368.9. Lamont A, Lyons MD, Jaki T, et al. Identification of predicted individual treatment effects in randomized clinical trials. Statistical methods in medical research 2018;27(1):142-157. 10. Mitchell GK, Hardy JR, Nikles CJ, et al. The effect of methylphenidate on fatigue in advanced cancer: An aggregated N-of-1 trial. Journal of pain and symptom management 2015;50(3):289-296. 11. Blackston J, Chapple A, McGree J, McDonald S, Nikles J. Comparison of Aggregated N-of1 Trials with Parallel and Crossover Randomized Controlled Trials Using Simulation Studies. Healthcare 2019;7(4):137. 12. Bradbury J, Avila C, Grace S. Practice-Based Research in Complementary Medicine: Could N-of-1 Trials Become the New Gold Standard? Healthcare 2020;8(1):15.13. Schork NJ. Personalized medicine: Time for one-person trials. Nature 2015;520(7549):609-611. 14. Goetz LH, Schork NJ. Personalized medicine: motivation, challenges, and progress. Fertility and Sterility 2018;109(6):952-963. 15. Tate RL, Perdices M, Rosenkoetter U, et al. Revision of a method quality rating scale for singlecase experimental designs and n-of-1 trials: The 15-item Risk of Bias in N-of-1 Trials (RoBiNT) Scale. Neuropsychological rehabilitation 2013;23(5):619-638. 16. Porcino AJ, Punja S, Chan AW, et al. Protocol for a systematic review of N-of-1 trial protocol guidelines and protocol reporting guidelines. Systematic reviews 2017;6(1):1-5. 17. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic reviews 2016;4(1):1. 18. Van Karnebeek CDM, Stockler S. Treatable inborn errors of metabolism causing intellectual disability: A systematic literature review. Molecular Genetics and Metabolism 2012;105(3):368-381. 19. Van Karnebeek CDM, Shevell M, Zschocke J, Moeschler JB, Stockler S. The metabolic evaluation of the child with an intellectual developmental disorder: Diagnostic algorithm for identification of treatable causes and new digital resource. Molecular Genetics and Metabolism 2014;111(4):428-438. Annelieke Muller sHL.indd 51 14-11-2023 09:07